R
LIVE

Serial Number

79396229

Owner

Rejuvenate Biomed NV

Attorney

Cheryl L. Burbach

Filing Date

Apr 12, 2024

Add to watchlist:

No watchlists yet
View on USPTO

R Trademark

Serial Number: 79396229 • Registration: 7943034

R is a trademark filed by Rejuvenate Biomed NV on April 12, 2024. The trademark is classified under Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific). The application is currently registered and active.

Owner Contact Info

Rejuvenate Biomed NV (3 trademarks)

Agoralaan A bis
B-3590 Diepenbeek , BE

Entity Type: 32

Trademark Details

Filing Date

April 12, 2024

Registration Date

September 16, 2025

Published for Opposition

July 29, 2025

Goods & Services

Medical, biological, and pharmaceutical preparations for the treatment of viral infections, bacterial infections, cancer, viral, bacterial, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; veterinary preparations for pets, cattle, livestock, for the treatment of viral infections, bacterial infections, cancer, viral, bacterial, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; medical, biological, and pharmaceutical preparations for preventing and treating viral, bacterial, and yeast infections; veterinary preparations for pets, cattle, livestock, for preventing and treating viral, bacterial, and yeast infections; medical, biological, and pharmaceutical preparations for preventing and treating cancer, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; veterinary preparations for pets, cattle, livestock for preventing and treating cancer, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; vaccines; sanitary preparations for medical purposes; dietary supplements and dietetic preparations adapted for medical purposes; dietetic foods adapted for medical use; diagnostic preparations for medical purposes; diagnostic chemical reagents for medical use; clinical medical reagents

Biological research; clinical research in the field of age-related diseases and cancer; medical research; research and development services in the field of pharmaceutical preparations; pharmaceutical products development; pharmaceutical product evaluation; research and development in the field of microorganisms and cells; research on the subject of pharmaceuticals; testing of pharmaceuticals; laboratory research services relating to pharmaceutical product development; development of gene-based medicines; drug discovery services; scientific research in the nature of conducting clinical trials for others relating to pharmaceutical products; scientific laboratory services; laboratory research services relating to pharmaceuticals; scientific risk assessment being consultation in the field of health risk assessment, namely, prediction and assessment of health risks to public and private agencies, facilities, individuals and locations following an accidental or terrorist caused release of chemical, biological, radiological or nuclear materials; consulting services in the field of pharmaceutical research; testing of pharmaceuticals being services for assessing the efficiency of pharmaceuticals; pharmaceutical toxicity testing for research purposes; pharmaceutical toxicity analysis services for scientific research purposes; computer services, namely, remote management of the information technology (IT) systems of others for the pharmaceutical and healthcare industries; conducting early evaluations in the field of new pharmaceuticals; providing information about scientific research, namely, the results of clinical trials for pharmaceutical products; providing medical and scientific research information in the field of pharmaceuticals and clinical trials; chemical research and analysis services; medical and pharmacological research services; scientific services, namely, scientific research in the field of genetics; scientific research for medical purposes in the field of age-related diseases and cancer; medical and scientific research, namely, conducting clinical trials for others; scientific research in the field of genetics; genetic mapping for scientific purposes; DNA screening for scientific research purposes; providing scientific research information in the field of pharmaceuticals for the treatment of medical disorders; technical research in the field of pharmaceutical studies; veterinary research; design and development of computer software relating to the medical field; design and development of computer software relating to healthcare; computer programming in the medical field; scientific computer programming services; providing temporary use of non-downloadable software for capturing, storing, processing, evaluating and reproducing medical and pharmaceutical data; providing temporary use of on-line non-downloadable computer programs on data networks using artificial intelligence (AI) for use in the life sciences research field, pharmaceutical research, medical research, drug discovery and development; platform as a service (PAAS) featuring computer software platforms using artificial intelligence (AI) for use in the life sciences research field, pharmaceutical research, medical research, drug discovery and development; software as a service (SaaS) services featuring software for capturing, storing, processing, evaluating and reproducing medical and pharmaceutical data in the life sciences research field, pharmaceutical research, medical research, drug discovery and development; software as a service (SaaS) featuring software using artificial intelligence (AI) for capturing, storing, processing, evaluating and reproducing medical and pharmaceutical data in the life sciences research field, pharmaceutical research, medical research, drug discovery and development; software as a service (SaaS) featuring software using artificial intelligence (AI) for analysis of self-assessment of illnesses; software as a service (SaaS) featuring software using artificial intelligence (AI) for machine learning in the field of healthcare; software as a service (SaaS) featuring health monitoring software; software as a service (SaaS) featuring software for analyzing biological genetic data; technology consultation in the field of artificial intelligence (AI); research in the field of artificial intelligence (AI)

Filing History

FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Dec 16, 2025 FICR
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
Nov 22, 2025 OPNX
NEW REPRESENTATIVE AT IB RECEIVED
Nov 14, 2025 NREP
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Oct 22, 2025 OPNS
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
Oct 22, 2025 OPNR
NOTICE OF REGISTRATION CONFIRMATION EMAILED
Sep 16, 2025 NRCC
REGISTERED-PRINCIPAL REGISTER
Sep 16, 2025 R.PR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Jul 29, 2025 NPUB
PUBLISHED FOR OPPOSITION
Jul 29, 2025 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Jul 23, 2025 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Jun 20, 2025 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
May 1, 2025 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
May 1, 2025 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
May 1, 2025 TROA
NEW REPRESENTATIVE AT IB RECEIVED
Mar 28, 2025 NREP
REFUSAL PROCESSED BY IB
Nov 23, 2024 RFNT
CHANGE OF NAME/ADDRESS REC'D FROM IB
Nov 8, 2024 ADCH
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Nov 5, 2024 RFCS
REFUSAL PROCESSED BY MPU
Nov 5, 2024 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Oct 30, 2024 RFCR
NON-FINAL ACTION WRITTEN
Oct 29, 2024 CNRT
ASSIGNED TO EXAMINER
Oct 25, 2024 DOCK
APPLICATION FILING RECEIPT MAILED
Jun 3, 2024 MAFR
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Jun 3, 2024 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
May 23, 2024 REPR